Evidence map›Paper›PMID 26973422›Full record

ArticleWorld journal of gastroenterology2016

Importance of SALL4 in the development and prognosis of hepatocellular carcinoma.

Fei Yin, Xin Han, Shu-Kun Yao, Xiao-Ling Wang, Hui-Chai Yang

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Knockdown ofAnnals of translational medicine · 2020
    Article
  16. Biomarkers for hepatocellular cancer.World journal of hepatology · 2020
    Review
  17. Article
  18. Article
  19. Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Fei YinFei Yin, Xin Han, Department of Gastroenterology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
Xin HanFei Yin, Xin Han, Department of Gastroenterology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
Shu-Kun YaoFei Yin, Xin Han, Department of Gastroenterology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
Xiao-Ling WangFei Yin, Xin Han, Department of Gastroenterology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
Hui-Chai YangFei Yin, Xin Han, Department of Gastroenterology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
Fourth Hospital of Hebei Medical University · CNChina-Japan Friendship Hospital · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo detect the expression of sal-like protein 4 (SALL4) and to explore its relationship with clinicopathological characteristics and prognosis of hepatocellular carcinoma (HCC).

methodsOne hundred and twenty-six samples of HCC tissue, 44 of adjacent noncancerous cirrhotic tissue and 10 of liver hemangioma tissue, were obtained from patients who underwent hepatectomy for HCC at the Fourth Hospital of Hebei Medical University. None of the patients had received any form of treatment before the operation. After resection, all the tissues were fixed in 10% neutral formaldehyde and embedded in paraffin. Expression of SALL4 was detected by immunohistochemistry. Patients were followed up for postoperative survival until February 2014. The relationships between SALL4 expression level and clinicopathological data and prognosis of HCC were analyzed.

resultsSALL4 expression was negative in the 10 samples of tissue from liver hemangioma, was weakly positive in the two samples from adjacent noncancerous cirrhotic tissue, and positive in 58 samples of HCC tissues. The differences were statistically significant (P < 0.05). Expression of SALL4 was higher in patients with higher α-fetoprotein (AFP) levels, portal vein tumor thrombus, and later clinical stage based on the Barcelona Clinic Liver Cancer classification (P < 0.05). Among patients with negative expression, weakly positive expression, positive expression, and strongly positive expression of SALL4, the median survival time was 39, 25, 23, and 9 mo, respectively (P < 0.001). When both AFP and SALL4 were detected, patients who were negative for both AFP and SALL4, SALL4-positive only, AFP-positive only, and positive for both AFP and SALL4, had a median survival time of 41, 38, 31, and 12 mo, respectively (P < 0.001).

conclusionExpression of SALL4 is relevant to the prognosis of HCC patients. Patients with higher expression levels of SALL4 and AFP have worse prognosis.

Indexed as

Hepatectomyalpha-FetoproteinsBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesChinaFemaleHumansImmunohistochemistryKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingProportional Hazards ModelsRisk FactorsAFP protein, humanalpha-FetoproteinsBiomarkers, TumorSALL4 protein, humanTranscription FactorsHepatocellular carcinomaPrognosisSal-like protein 4Survival analysisα-Fetoprotein

Identifiers

PMID26973422
PMCPMC4778006
OpenAlexW2297505533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.